Market Performance - The Hong Kong stock market showed a mixed performance with the Hang Seng Index rising by 0.95% to 26,630.54 points, the Hang Seng Tech Index increasing by 0.56% to 5,137.84 points, and the National Enterprises Index up by 0.51% to 8,859.49 points [1] - Major tech stocks exhibited varied movements, with Alibaba down by 0.07%, Tencent up by 1.17%, and Netease rising by 2.4% [1] Corporate Earnings - Baidu Group reported a total revenue of 32.7 billion yuan for Q4, a 5% quarter-on-quarter increase, with a NON-GAAP net profit of 3.9 billion yuan [2] - NIO's subsidiary, Shenji, signed a final agreement for a 2.257 billion yuan investment, focusing on smart driving chip business [2] Energy and Gaming Sector - Zhengli New Energy expects a net profit of 680 million to 820 million yuan for 2025, representing a year-on-year growth of approximately 647.25% to 801.10% [3] - Galaxy Entertainment anticipates a net income of 49.2 billion HKD for 2025, up 13% year-on-year, with a net profit increase of 22% [3] Financial and Real Estate Sector - Hong Kong Exchanges and Clearing reported total revenue of 29.161 billion HKD for 2025, a 30% year-on-year increase, with a net profit of 17.754 billion HKD, up 36% [4] - Sun Hung Kai Properties achieved revenue of 52.705 billion HKD for the six months ending December 31, 2025, a 31.98% increase year-on-year [4] Consumer and Healthcare Sector - Chow Tai Fook reported revenue of 10.485 billion HKD for the six months ending December 31, 2025, with a net profit increase of 15% [5] - Jiangnan Buyi's total revenue for the same period was approximately 3.376 billion HKD, up 7% year-on-year [5] - CanSino Biologics reported total revenue of 1.068 billion HKD for 2025, a 26.18% year-on-year increase [5] Other Corporate Earnings - BioAstute expects 2025 revenue of approximately 1.379 billion HKD, a 40.63% increase year-on-year [7] - Weitai Medical anticipates revenue of no less than 650 million yuan for 2025, an 88.1% year-on-year growth [7] Institutional Insights - UBS analysts believe that concerns regarding AI have created buying opportunities, increasing the weight of tech stocks in their portfolio [9] - Guoyuan International suggests that external environment improvements will likely lead to a bullish trend for Hong Kong stocks [10] - China Galaxy Securities highlights three investment directions: rising geopolitical risks, consumer sector recovery, and long-term tech investments [11]

Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.75% to 26,578.43 points, the Hang Seng Tech Index up by 1.03% to 5,162.13 points, while the Red Chip Index fell by 0.1% to 4,407.39 points [1] - Major tech stocks rebounded, with Alibaba up 1.05%, Tencent up 2.83%, and Netease up 2.8%, while Xiaomi fell by 0.34% [1] Corporate Earnings - Baidu Group reported a total revenue of 32.7 billion yuan for Q4 2025, a 5% increase quarter-on-quarter, with a NON-GAAP net profit of 3.9 billion yuan [2] - NIO's subsidiary, Shenji, signed a final agreement for a 2.257 billion yuan investment, focusing on smart driving chip business, maintaining a 62.7% indirect stake [2] Energy and Gaming Sector - Zhengli New Energy expects a net profit of 680 million to 820 million yuan for 2025, a year-on-year increase of approximately 647.25% to 801.10% due to significant growth in battery product sales [3] - Galaxy Entertainment reported a net income of 49.2 billion HKD for 2025, a 13% year-on-year increase, with net profit rising by 22% to 10.7 billion HKD [3] Financial and Real Estate Sector - Hong Kong Exchanges and Clearing reported total revenue of 29.161 billion HKD for 2025, a 30% year-on-year increase, with net profit rising by 36% to 17.754 billion HKD [4] - Sun Hung Kai Properties announced a revenue of 52.705 billion HKD for the first half of 2025, a 31.98% increase, with profit rising by 36.21% to 10.247 billion HKD [4] Consumer and Healthcare Sector - Chow Tai Fook reported a revenue of 10.485 billion HKD for the first half of 2025, with a net profit increase of 15% to 1.3343 billion HKD [5] - Jiangnan Buyi reported total revenue of approximately 3.376 billion HKD for the first half of 2025, a 7% increase, with profit rising by 11.9% to 676 million HKD [5] - CanSino Biologics reported total revenue of 1.068 billion HKD for 2025, a year-on-year increase of 26.18%, with a net profit of 27.827 million HKD [5] Other Corporate Growth - Baidu's revenue is expected to reach approximately 1.379 billion HKD for 2025, a 40.63% year-on-year increase, with net profit rising by 416.37% to 173 million HKD [6] - Weitai Medical expects revenue of no less than 650 million yuan for 2025, an increase of approximately 88.1% [7] Institutional Insights - UBS analysts believe that concerns over AI have created buying opportunities, increasing the weight of tech stocks in their portfolio [8] - Guoyuan International suggests that external environment improvements will boost market sentiment, leading to a potential upward trend in Hong Kong stocks [9] - China Galaxy Securities highlights three investment directions: rising geopolitical risks benefiting precious metals and energy, consumer sector growth due to policy support, and long-term investment in tech stocks [10] - CMB Securities emphasizes the undervaluation of the Hong Kong tech sector, suggesting high odds for future gains [11]

Market Overview - The Hong Kong stock market opened higher on February 27, with the Hang Seng Index rising by 0.25% to 26,447.05 points, the Hang Seng Tech Index up by 0.15% to 5,117.24 points, and the National Enterprises Index increasing by 0.04% to 8,817.53 points. The Red Chip Index fell by 0.06% to 4,409.07 points [1] Company Performance - Baidu Group-SW reported a total revenue of 32.7 billion yuan for Q4 2025, a 5% quarter-on-quarter increase, with a NON-GAAP net profit of 3.9 billion yuan. The smart cloud infrastructure revenue reached 5.8 billion yuan, and AI high-performance computing subscription revenue grew by 143% year-on-year [2] - Galaxy Entertainment's net income for 2025 was 49.2 billion HKD, a 13% year-on-year increase, with a net profit of 10.7 billion HKD, up 22% year-on-year [2] - Hong Kong Exchanges and Clearing reported total revenue of 29.161 billion HKD for 2025, a 30% year-on-year increase, with a net profit of 17.754 billion HKD, up 36% year-on-year [2] - New World Development announced a revenue of 52.705 billion HKD for the six months ending December 31, 2025, a 31.98% year-on-year increase, with a profit of 10.247 billion HKD, up 36.21% year-on-year [2] - Chow Tai Fook reported a revenue of 10.485 billion HKD for the six months ending December 31, 2025, with a net profit growth of 15% to 1.3343 billion HKD [3] - Jiangnan Buyi's total revenue for the same period was approximately 3.376 billion yuan, a 7% year-on-year increase, with a profit of 676 million yuan, up 11.9% year-on-year [3] - Biotech company Kangsino Biologics reported total revenue of 1.068 billion yuan for 2025, a 26.18% year-on-year increase, with a net profit of 27.827 million yuan, turning profitable [3] Earnings Forecasts - Zhenhua Education Group expects 2025 revenue to be between 1.8 billion and 2.0 billion yuan, a year-on-year growth of approximately 63.3% to 81.5%, with net profit expected between 260 million and 340 million yuan, a year-on-year increase of approximately 35.2% to 76.8% [4] - Feida Holdings anticipates a net profit of no less than 100 million HKD for the year [4] Strategic Developments - NIO's subsidiary Shenji has entered into a final agreement for a 2.257 billion yuan investment related to NIO's smart driving chip business, maintaining a 62.7% indirect stake post-transaction [5] - MIRES-B has signed a memorandum of understanding with AHLL for strategic cooperation [5] - Several companies, including ZTO Express, Xiaomi Group, and NetEase Cloud Music, have initiated stock buybacks, indicating confidence in their future development [5] Market Insights - According to Ping An International, the current macro data vacuum and policy expectations around the National People's Congress may lead to continued appreciation of the RMB and increased foreign capital inflow, which could strengthen the spring market [6] - China Galaxy Securities highlights three key areas for future investment focus: rising geopolitical risks in the Middle East benefiting precious metals and energy sectors, consumer sector valuations at relatively low levels with potential for growth, and the technology sector as a long-term investment focus amid ongoing AI advancements [6]

Major Events - 德视佳 (01846) plans to acquire FYEO Europe B.V., a leading refractive surgery company in the Netherlands, with a significant investment [1] - 美格智能 (03268) is set to launch an IPO from February 27 to March 5, aiming to globally offer 35 million H-shares [1] - 埃斯顿 (02715) will also conduct an IPO from February 27 to March 4, with a global offering of 96.78 million H-shares [1] - 兆威机电 (02692) is expected to list on March 9 after its IPO from February 27 to March 4 [1] - 优乐赛共享 (02649) plans to globally offer 20.336 million H-shares during its IPO from February 27 to March 4 [1] - 蔚来-SW (09866) subsidiary has signed a final agreement for a 2.257 billion RMB investment [1] - 贪玩 (09890) has secured exclusive operation rights for the game "天龙八部2：飞龙战天" and invested in game developer 上海阅龙 [1] - 贝康医疗-B (02170) received a medical device registration certificate from the National Medical Products Administration for its Geri embryo culture solution [1] Operating Performance - 百度集团-SW (09888) reported Q4 revenue of 32.7 billion RMB, a 5% quarter-on-quarter increase, with "萝卜快跑" total order volume growing over 200% year-on-year [2] - 香港交易所 (00388) announced a 2025 full-year profit attributable to shareholders of 17.754 billion HKD, a 36% year-on-year increase [2] - 新鸿基地产 (00016) reported a mid-year profit attributable to shareholders of 10.247 billion HKD, a 36.21% year-on-year growth [2] - 银河娱乐 (00027) posted an annual profit attributable to shareholders of 10.7 billion HKD, a 22% increase year-on-year [2] - 周大福创建 (00659) reported a mid-year profit attributable to shareholders growing 15% year-on-year to 1.3343 billion HKD [2] - 百济神州 (06160) showed strong growth in 2025 with an adjusted net profit of approximately 918 million USD, returning to profitability [2] - 再鼎医药 (09688) reported total revenue of 460.2 million USD in 2025, a 15% year-on-year increase, with significant progress in its global innovation pipeline [2] - 百奥赛图-B (02315) released a 2025 annual performance report showing a net profit of 173 million RMB, a 416.37% year-on-year increase [2] - 康希诺生物 (06185) reported a 2025 annual performance report with a net profit of 27.827 million RMB, returning to profitability [2] - 中电控股 (00002) announced an annual profit attributable to shareholders of 10.468 billion HKD, a 10.85% year-on-year decrease [2] - 正力新能 (03677) expects a net profit increase of up to eight times in 2025, estimated at 680 to 820 million RMB, significantly exceeding market expectations [2] - 至源控股 (00990) issued a profit warning, anticipating a 126% year-on-year increase in net profit to approximately 840 million RMB in 2025 [2]

Core Insights - The company has received a Class III medical device registration certificate for its Geri embryo culture medium from the National Medical Products Administration of China, marking a significant milestone in its product development [1] - The Geri embryo culture medium has already obtained certifications from CE, FDA, and TGA, indicating its international compliance and readiness for clinical use [1][2] - The product addresses the challenges faced by older patients in embryo cultivation through its antioxidant formula and stable osmotic pressure environment, enhancing clinical pregnancy rates [2] Product Development - The Geri embryo culture medium is designed specifically to tackle fertility issues in older patients, featuring a "triple antioxidant protection network" that mitigates oxidative stress in older embryos [2] - The inclusion of human serum albumin and long-term stability simplifies laboratory operations and ensures a stable cultivation environment [2] - International clinical validation shows that the combination of Geri embryo culture medium with the Geri wet incubator and AI embryo assessment system significantly improves the quality blastocyst rate and clinical pregnancy rate [2] Market Position - The approval of the Geri embryo culture medium signifies the company's transition from technology introduction to localized production, filling a gap in the domestic high-end assisted reproductive consumables market [2] - The company is the first in China to hold FDA, CE, TGA, and NMPA certifications, establishing a strong competitive position in the industry [2] - With core PGT technology and self-supply capabilities, the company has covered most PGT licensed institutions nationwide and established numerous localized laboratories, creating a sustainable ecological barrier [2]

Core Viewpoint - The approval of Geri embryo culture medium by the National Medical Products Administration (NMPA) in China marks a significant milestone for the company, enabling it to address the challenges faced by older patients in embryo cultivation and filling a gap in the domestic high-end assisted reproductive consumables market [1][2]. Group 1 - The Geri embryo culture medium received a Class III medical device registration certificate from the NMPA on February 25, 2026 [1]. - Prior to this approval, the Geri embryo culture medium had already obtained certifications from the European Union (CE), the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA) [1]. - The core technology of the Geri embryo culture medium is derived from the Sydney IVF Center, and it combines with the Geri wet incubator and AI embryo assessment system to enhance clinical practice in China [1]. Group 2 - The technology focuses on creating a systematic solution for fertility challenges faced by older patients, featuring a "triple antioxidant protection network" that effectively addresses oxidative stress in older embryos [2]. - The combination of the culture medium with the Geri wet incubator and AI embryo assessment system has been clinically validated to significantly improve the rates of quality blastocysts and clinical pregnancy, providing strong support for older fertility [2]. - The approval signifies a critical transition for the company from technology introduction to localized production, making it the first Chinese enterprise to hold FDA, CE, TGA, and NMPA certifications [2].

Core Viewpoint - The approval of Geri embryo culture medium by the National Medical Products Administration (NMPA) in China marks a significant milestone for the company, establishing it as the first Chinese enterprise to obtain FDA, CE, TGA, and NMPA certifications for high-end assisted reproductive materials [1][2]. Group 1: Product Approval and Certifications - The Geri embryo culture medium received its Class III medical device registration certificate from the NMPA on February 25, 2026 [1]. - Prior to this approval, the Geri embryo culture medium had already obtained certifications from the European Union (CE), the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA) [1]. Group 2: Technological Advantages - The core technology of the Geri embryo culture medium addresses fertility challenges for older patients through a systematic solution, featuring a "triple antioxidant protection network" that effectively mitigates oxidative stress in older embryos [2]. - The product simplifies laboratory operations and ensures a stable culture environment by incorporating human serum albumin and ultra-long-term stability [2]. Group 3: Clinical Impact and Market Position - International clinical validation indicates that the Geri embryo culture medium, when combined with the Geri wet incubator and AI embryo assessment system, significantly enhances the rates of high-quality blastocysts and clinical pregnancy [2]. - The approval signifies a critical transition from technology introduction to localized production, filling a gap in the domestic market for high-end assisted reproductive consumables [2]. - The company has established a strong presence across most PGT licensed institutions in China and operates numerous localized laboratories, creating a sustainable ecological barrier for continuous innovation [2].

Suzhou Basecare Medical Corporation Limited 蘇 州 貝 康 醫 療 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2170） 自願公告 Geri胚胎培養液（Gems胚胎培養液系列產品之一） 獲國家藥監局頒發醫療器械註冊證 本公告由蘇州貝康醫療股份有限公司（「本公司」，連同其子公司統稱「本集團」） 自願刊發，以告知本公司股東及潛在投資者有關本集團業務的最新發展。 本公司董事會（「董事會」）欣然宣佈，本公司的Geri胚胎培養液（Gems胚胎培養 液系列產品之一）於2026年2月25日獲得中國國家藥品監督管理局（「國家藥監局」） 頒發的三類醫療器械註冊證（註冊證號：國械註進20263180071）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 此次獲批標誌著公司實現從引進技術到本土化生產的關鍵跨越，填補國產高 端輔助生殖耗材空白，成為首 ...